Market Analysis

Global immunology market

The new global immunology report concludes that diseases like AIDS are increasing the casualty’s day by day and the new patients diagnosed with such infectious diseases are also increasing at an alarming rate. The global increase in infectious diseases indicates that the body’s immune system has gone down in the human raise and this is letting the body easily accessible. All these points narrow down to the fact that the increase in the infectious diseases is going to the primary key for the growth of the immunological market and the demand for immunological products will be at its peak.

Immunomodulators are an effective way to treat infectious diseases like AIDS, where the patient’s immune system is boosted and resist against the pathogens are acquired. It is estimated that the global immunology market with grow at a steady CAGR of about 5% by 2022.

The manufacturers have come up with new therapeutic agents which are still awaiting the standardized approval. The introduction of these new agents and therapeutic techniques will take the market to a new level of progress. Manufacturers and scientists are currently focusing on new advanced drugs in immunotherapy. The competition in the immunology market is primarily based on piece, quality, innovation etc.

Based on the recent report, worldwide cancer affects more than 10 million people every year and the incidence of deaths are projected to continue rising, with an estimated 13.1 million deaths in 2030 (about a 70% increase) around 22% of all deaths not related to communicable diseases. Rise in cancer research, increase in cancer prevalence and surge in association between pharmaceutical companies the core factors that enhance the growth of cancer therapeutics market.

With the fruitful synergistic interactions and discussions, learnings, partnerships and associations at this yearly meeting, we anticipate getting together to unveil the challenges by improvising the early diagnosis and detection of cancer research for better outcomes of patients.

Both immunosuppressants and immuno boosters are marketed at almost the same rate but the market of immunosuppressants have a slight increase in the recent years as the need for anti-transplant rejection drugs are increasing due to the numerous organ transplant that takes place every day. USA will be the prime revenue generator as the therapeutic advancements are high in the country.

Major immunology drug producers in Spain
- Eli Lilly
- ABAC Therapeutics
- Adienne Pharma and Biotech
- Aelix Therapeutics